- Home
- FTHM vs CUE Comparison
FTHM vs CUE Comparison
Compare FTHM & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | CUE |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 27.1M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FTHM | CUE |
|---|---|---|
| Price | $1.00 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $3.00 |
| AVG Volume (30 Days) | 102.1K | ★ 386.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.21 | ★ 35.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $335,184,000.00 | $9,287,000.00 |
| Revenue This Year | $30.07 | N/A |
| Revenue Next Year | $14.66 | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.65 | $0.23 |
| 52 Week High | $3.37 | $1.26 |
Technical Indicators
Market Signals| Indicator | FTHM | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 40.92 |
| Support Level | $0.90 | $0.28 |
| Resistance Level | $1.50 | $0.36 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 34.52 | 29.81 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.